Best Genomics Companies in Germany
The 261 best Genomics companies in Germany in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: ATAI.
Germany's Genomics sector has 261 tracked companies and $1.5 billion in disclosed funding, and this directory ranks them by equity raised and recent momentum. That's the number that tells you who's actually capitalized to compete. Atai leads the pack at $387 million raised, a figure that dwarfs the next tier: Curetis at $127 million, Ethris at $26 million, Isar Bioscience at $23 million. One unicorn sits in the mix. The global market was valued at roughly $24.3 billion in 2021 and is forecast to reach $85.1 billion by 2030 at a 16.37% CAGR, driven by declining sequencing costs and accelerating demand for personalized medicine.
So what's pulling capital into Germany specifically? Hot themes right now include pharmacogenomics, hereditary disease diagnostics, and machine learning drug discovery, and as shown in 2011 research, the foundational sequencing economics underpinning all of it have been compressing for over a decade. Backers like HTGF, EIC Fund, and Kfw are the most active investors here, I'd note that public capital sources feature heavily, which reflects both the regulatory environment and Germany's deliberate push to anchor biotech infrastructure domestically. If you're trying to understand where the real funding weight sits, start with Atai, then work down.
- Genomics Market Surges with PCR and AI Technologies Projected to Reach
Our analysis of 50 Genomics companies
$7.8b in tracked funding; 84% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Genomics companies in Germany
| # | Company | Disclosed funding | Last round | Employees | Founded | Founder | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ATAI 🦄 Biopharmaceutical company accelerating the development of mental health treatments | $387M | 63 mo ago | 119 | 2018 | Lars Christian Wilde Co-Founder | — | — | — |
| 2 | Ganymed Pharmaceuticals Developer of antibody-based drugs for the treatment of solid cancers | $212M | 151 mo ago | 4 | 2001 | — | — | 1,019 patents Targeted antibody therapeutics against claudin‑6 and claudin‑18.2 for oncology | — |
| 3 | Isarna Therapeutics Developer of TGF-B inhibitors based therapies for ophthalmic, fibrotic diseases and cancer | $158M | 145 mo ago | 3 | 1998 | — | — | 64 patents Antisense oligonucleotide therapeutics targeting TGF‑β pathways for ocular disease treatment | — |
| 4 | Curetis Provider of molecular diagnostics platform to detect infectious diseases | $127M | 68 mo ago | 55 | 2007 | Raju Jha CEO | Wix eCommerceWixSentry+10 | 79 patents Automated nucleic acid extraction and sample lysis technologies for molecular diagnostic platforms. | — |
| 5 | Singleron Developer of single-cell multi-omics platform for clinical research and molecular diagnosis | $84M | 55 mo ago | — | 2018 | Jing Zhou Co-Founder | WordPressMySQLPHP+16 | — | — |
| 6 | Ingenium Pharamceutical Discovering drug targets through Deductive Genomics | $71M | 242 mo ago | 41 | 1999 | John Watkins President & CEO | — | — | — |
| 7 | Epigenomics Molecular Diagnostics for Cancer | $53M | 65 mo ago | 32 | 1998 | Greg Hamilton CEO | WordPressMySQLPHP+12 | 793 patents DNA methylation‑based liquid biopsy biomarkers for early cancer detection and prognosis | — |
| 8 | GPC Biotech Developing oncology therapies | $44M | 228 mo ago | — | 1997 | Elmar Maier Co-Founder | — | 128 patents Developing kinase inhibitor small molecules and hybrid screening assays for cancer therapy. | — |
| 9 | Breakpoint Therapeutics Provider anti-cancer drug based on DNA repair mechanism | $34M | 83 mo ago | 5 | 2019 | — | — | 15 patents Inhibiting DNA repair enzymes (polymerase θ, Werner helicase) for cancer therapeutics | — |
| 10 | Cevec Pharmaceuticals Provider of glyco-optimised human cell lines and gene therapy vectors using proprietary cell expression system | $28M | 58 mo ago | 39 | 2001 | — | — | 208 patents Production and engineering of viral vectors and glyco-modified recombinant therapeutics. | — |
| 11 | Centogene Provider of biochemical/genetic tests to detect mutations and rare diseases | $28M | 52 mo ago | 657 657 → 481 (-27%) · sector median -24% | 2006 | — | WordPress Block EditorWordPressApple iCloud Mail+20 | 156 patents Genetic and molecular diagnostics for lysosomal storage and cystic fibrosis diseases | — |
| 12 | SpinDiag Developer of point-of-care system for screening drug-resistant pathogens | $28M | 44 mo ago | 74 | 2016 | Frank Schwemmer Co-Founder | — | 39 patents Magnetic‑rotational sample preparation and lysis for nucleic‑acid extraction and analysis | — |
| 13 | Ethris Developer of mRNA therapeutics for infectious diseases 55Patents top 25%Talent top 28%Moat top 29%Product top 30% All 11 signals ▾Patentstop 25% Talenttop 28% Moattop 29% Producttop 30% Innovationtop 35% Fundingtop 36% Growthtop 48% Techbottom 48% Marketbottom 44% Globalbottom 42% Newsbottom 27% Patents: 387 patents matched (strict assignee match) · 116 filings since 2022 vs 192 in 2017-21 Talent: Analyst team rating 4/5 rank vs industry peers · Fliar Intelligence Index 55/100 | $26M | 13 mo ago | 49 49 → 34 (-31%) · sector median -24% | 2009 | — | JimdoApple iCloud MailMicrosoft 365+10 | 387 patents mRNA therapeutics composition, manufacturing, and stabilization technologies | — |
| 14 | ISAR Bioscience Developer of regenerative medicine | $23M | 31 mo ago | 19 | 2018 | — | Master SliderWordPressMySQL+18 | 15 patents Patents concentrated in chemistry & materials | — |
| 15 | GNA Biosolutions Develops instruments, OEM modules and assays for molecular pathogen detection | $20M | 82 mo ago | 29 | 2010 | — | — | 96 patents Patents concentrated in chemistry & materials | — |
| 16 | Ayoxxa Biosystems Developer of a platform for multiplex protein analysis | $19M | 113 mo ago | 40 | 2010 | — | — | 4 patents Patents concentrated in computing, sensing & instrumentation | — |
| 17 | Mainz BioMed Provider of diagnostic kits for colorectal cancer 40Funding top 36%Tech top 45%News top 47%Patents top 48% All 10 signals ▾Fundingtop 36% Techtop 45% Newstop 47% Patentstop 48% Marketbottom 49% Moatbottom 49% Talentbottom 49% Innovationbottom 46% Growthbottom 42% Globalbottom 32% Funding: Raised $17.3M across 2 rounds · 2 rounds over 3 yrs (0.7/yr) Tech: 35 technologies across 3/8 capability areas · Cloud: Cloudflare rank vs industry peers · Fliar Intelligence Index 40/100 | $17M | 4 mo ago | 64 | 2021 | Guido Baechler CEO | WordPressMySQLPHP+32 | 7 patents Predictive biomarkers for colorectal adenoma and cancer progression risk assessment | 2 launchs · 1 partnership · 1 expansion |
| 18 | mbiomics Provider of a genomic-based platform for microbiome-based therapeutics development 21Funding top 39%Patents top 39%Moat top 42%Innovation top 50% All 6 signals ▾Fundingtop 39% Patentstop 39% Moattop 42% Innovationtop 50% Globalbottom 36% Marketbottom 26% Funding: Raised $14.0M across 2 rounds · 2 rounds over 3 yrs (0.7/yr) Patents: 13 patents matched (strict assignee match) · 13 filings since 2022 vs 0 in 2017-21 rank vs industry peers · Fliar Intelligence Index 21/100 | $14M | 1 mo ago | 7 | 2020 | — | — | 13 patents RNA purification methods and microbiome analysis/composition technologies for diagnostic applications | — |
| 19 | Miltenyi Biotec Develops tools and products for research and clinical application | $13M | 63 mo ago | 585 | 1989 | Stefan Miltenyi Founder & MD | Cart FunctionalityApple iCloud MailMicrosoft 365+19 | 875 patents Advanced cell therapy manufacturing, immune cell engineering, and microfluidic sorting platforms | — |
| 20 | Seamless Therapeutics Provider of gene-editing platform for targeted therapeutics | $12M | 39 mo ago | — | 2022 | Anne Heninger Co-Founder | WordPress Block EditorwpBakeryWordPress+22 | 4 patents Engineered large serine recombinases/integrases for precise genome editing applications. | — |
| 21 | amaxa biosystems Amaxa Biosystems develops and commercializes gene transfer technologies and products. | $12M | 300 mo ago | 160 | 1998 | — | — | — | — |
| 22 | GeneQuine Developer of gene therapies for the treatment of musculoskeletal disorders | $10M | 64 mo ago | 6 | 2012 | Kilian Guse Co-Founder & CEO | — | — | — |
| 23 | Signature Diagnostics Molecular diagnostic products for cancer | $8M | 214 mo ago | 28 | 2004 | Andre Rosenthal CEO | — | 45 patents Patents concentrated in chemistry & materials | — |
| 24 | Alacris Theranostics Genomics service provider | $7M | 89 mo ago | 20 20 → 13 (-35%) · sector median -24% | 2009 | Hans Lehrach Founder | WordPress Block EditorWordPressMySQL+16 | 41 patents Molecular diagnostics and biomarker discovery using nanotech optical detection and therapy efficacy assays | — |
| 25 | New Oncology Provider of pharmacogenomics tests for cancer | $6M | 128 mo ago | 30 | 2012 | — | — | — | — |
| 26 | Nostos Genomics Developer of AI platform for interpretation of genetic variants and mutations | $6M | 52 mo ago | 20 | 2018 | — | — | 3 patents Computational tools for classifying and prioritizing genetic variants in genomics | — |
| 27 | faCellitate Developer of synthetic coatings and surface technologies for cell culture applications | $4M | 45 mo ago | 50 | 2019 | Simon Widmaier Co-Founder & Managing Director | WordPressMySQLPHP+47 | 13 patents Cell‑culture surface coating polymers and biocompatible device attachment technologies | 1 partnership |
| 28 | FRIZ Biochem DNA-chip based biosensor for SNP detection | $3M | 138 mo ago | — | 2003 | Gerhard Hartwich CEO | — | 63 patents Patents concentrated in transport & manufacturing processes | — |
| 29 | Genome Biologics Developer of therapies for cardiovascular and cardiometabolic diseases | $3M | 57 mo ago | 12 | 2016 | Jonathan Ward Co-Founder | — | 23 patents Human cardiac organoid and tissue-mimetic platforms for disease modeling and drug screening | — |
| 30 | RoBoTec PTC Developer of automated plant production systems using artificial intelligence and robotics | $3M | 49 mo ago | 15 | 2019 | Friederike Rundstedt Co-Founder | SilverstripePHPBootstrap+7 | — | — |
| 31 | Biologs Provider of genetic information management tool | $3M | 125 mo ago | 7 | 2013 | — | — | — | — |
| 32 | Abviris Provider of diagnostics solutions for HPV infections | $2M | 63 mo ago | 5 | 2014 | Stefan Raupach Co-Founder & General Manager | — | — | — |
| 33 | BioNTech IMFS Provider of CDMO specialized in cell and gene therapy products | $2M | 125 mo ago | 240 | 1997 | Stephan Muller Co-Founder & MD | — | — | — |
| 34 | BIOMES Provider of genetic testing serivces for gut health diagostics | $2M | 76 mo ago | 45 45 → 36 (-20%) · sector median -24% | 2017 | Paul Hammer Co-Founder & CEO | Cart FunctionalityWordPressApple iCloud Mail+31 | — | — |
| 35 | SYNLAB Provider of medical diagnosis and clinical laboratory analysis services | $2M | 113 mo ago | 28,693 | 1998 | Mathieu Floreani CEO | TYPO3 CMSApple iCloud MailMicrosoft 365+11 | 5 patents Renal disease prognostic biomarkers using homoarginine for clinical diagnostic prediction. | — |
| 36 | GenXPro Developer of molecular biology reagents and bioinformatics solutions | $2M | 77 mo ago | — | 2005 | Ralf Horres Co-Founder | WordPressMySQLPHP+16 | 8 patents Patents concentrated in chemistry & materials | — |
| 37 | Lucid Genomics Developer of AI-based platform to analyse genomic mutation detection and prioritization | $1M | 21 mo ago | — | 2024 | Uira Melo Co-Founder & CEO | Cart FunctionalitySquarespace CommerceSquarespace+14 | — | 1 launch · 3 partnerships |
| 38 | Oncgnostics Developer of epigenetic biomarkers for cancer detection and diagnosis | $1M | 33 mo ago | 12 12 → 19 (+58%) · sector median -24% | 2012 | — | WordPressMySQLPHP+23 | 22 patents Molecular diagnostic assays for cancer risk assessment, especially head‑and‑neck oncology | — |
| 39 | Baseclick Holders of rights to new procedures in click chemistry and DNA photography. | $1M | 44 mo ago | 14 14 → 10 (-29%) · sector median -24% | 2008 | — | Cart FunctionalityWooCommerceWordPress+26 | 119 patents Click‑chemistry platforms for modified mRNA synthesis and vaccine development | — |
| 40 | Riboxx Provider of siRNA reagents, miRNA mimics, and immunomodulators for research application | $1M | 137 mo ago | 4 | 2009 | Jacques Rohayem Founder & CEO | — | 59 patents RNA-based immunostimulatory agents for post‑exposure viral vaccines and cancer therapy | — |
| 41 | ALS Automated Lab Solutions Provider of single cell and colony isolation system | $1M | 65 mo ago | 27 | 1998 | — | — | 45 patents Automated capillary handling and cell sample processing for high‑throughput imaging assays | — |
| 42 | Molecular Networks Cheminformatics software for drug discovery | $1M | 61 mo ago | — | 1997 | Johann Gasteiger Founder | WordPressMySQLPHP+17 | — | — |
| 43 | geneXplain Provider of bioinformatics and systems biology software | $1M | 101 mo ago | — | 2010 | Edgar Wingender Founder & CEO | WordPress Block EditorWordPressMySQL+20 | 4 patents Small-molecule quinoxaline inhibitors of thioredoxin reductase for therapeutic use | — |
| 44 | Axolabs Preclinical to commercial scale research services for developing oligonucleotide therapeutics | $947K | 67 mo ago | 118 118 → 215 (+82%) · sector median -24% | 2000 | — | WordPressMySQLPHP+19 | 30 patents Sensitive detection technologies for oligonucleotide conjugates and nucleic acid diagnostics | — |
| 45 | Ibidi Products and reagents for cell-based assay and microscopy | $817K | 77 mo ago | — | 2001 | Valentin Kahl CEO | PrestaShopMySQLZoho+22 | 148 patents Microfluidic platforms for cell-based assays and microscopy sample handling. | 1 launch · 1 partnership |
| 46 | PEPperPRINT Provides the peptide microarray platform | $676K | 70 mo ago | 29 29 → 30 (+3%) · sector median -24% | 2010 | — | TYPO3 CMSPleskPHP+22 | 12 patents Patents concentrated in transport & manufacturing processes | 1 launch |
| 47 | myPOLS Biotec Provider of engineered DNA polymerases for molecular biology applications | $639K | 74 mo ago | 10 | 2014 | — | — | — | — |
| 48 | Computomics Provider of data analysis services for next-generation sequencing data for the crop science industry | $551K | 56 mo ago | 13 | 2012 | — | ContaoMicrosoft WordPHP+6 | — | 1 partnership |
| 49 | Leopard Provider of genomic-based test kits for diisease diagnostics | $545K | 33 mo ago | — | 2023 | Mikkel Noerholm Co-Founder & CEO | — | — | — |
Top 12 Genomics companies in Germany
#1
Series A · Munich, Bavaria · founded 2020 · 7 employees$14Mraised▾
Provider of a genomic-based platform for microbiome-based therapeutics development. It offers platforms that combine DNA and RNA analysis for single or molecule detection which includes GOLD for microbiome analysis, monitors to track microbiome modulation, and STRATOS for microbiome profiling.
- Apr 2026Series A$14.1M
- Mar 2023Series A$14M
#2
Public · Mainz, Rhineland-Palatinate · founded 2021 · 64 employees$17.3Mraised▾
Provider of diagnostic kits for colorectal cancer. The company's product ColoAlert is a PCR-based molecular genetic colorectal cancer early-detection stool test. It uses proprietary methods to analyze cell DNA for specific tumor markers combined with the fecal immunochemistry test (FIT) and is designed to detect tumor DNA and CRC cases in their earliest stages.
- Feb 2026Post IPO$3M
- Jun 2023Post IPO$14.3M
#3
Series B · Planegg, Bavaria · founded 2009 · 49 employees$26.3Mraised▾
Developer of mRNA therapeutics for infectious diseases. It has two proprietary platforms for SNIM RNA technology (Stabilized Non-Immunogenic mRNA) for transcript therapy and SNIM RNA delivery system. The platforms enable the designing of mRNA for the protein of interest and chemical modification of the nucleotide backbone to bypass the innate immune response and targeted delivery. The pipeline includes therapeutics for COVID-19, respiratory diseases, and Primary ciliary dyskinesia (PCD).
- May 2025Grant (prize money)$11.3M
- Jun 2024Series B$5M
- Feb 2022Series B$26.3M
- Jan 2020Grant (prize money)$550.3K
#4
ATAI 🦄Public · Munich, Bavaria · founded 2018 · 119 employees$386.7Mraised▾
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Its product candidates include COMP360/Psilocybin therapy, PCN-101/R-ketamine, RL-007/Compound, DMX-1002/Ibogaine, GRX-917/Deuterated etifoxine, VLS-01/DMT, EMP-01/MDMA derivative, RLS-01/Salvinorin A, KUR-101/Deuterated Mitragynine, and DMX-1001/Noribogaine. The business operates geographically in two regions being the United States and Germany.
#5
Funding Raised · Planegg, Bavaria · founded 2018 · 19 employees$23.1Mraised▾
ISAR Bioscience is the developer of regenerative medicine. The company uses the induced pluripotent stem cell and genome engineering technologies for developing regenerative medicine. It has collaboration with ldc and Assay.Works to develops therapeutic and discovery technology.
- Nov 2023Grant (prize money)$1M
- Grant (prize money)$22.1M
#6
Acquired · Holzgerlingen, Baden Wurttemberg · founded 2007 · 55 employees$127.1Mraised▾
Curetis provides a molecular diagnostics device to detect infectious diseases. The company focuses on multiparameter testing of many analytes in a single run, providing broad panels of combined pathogen and resistance gene detection for a wide range of diseases. The company develops the Unyvero A50 System for the detection of bacterial infections using PCR technology in hospitalized patients. Using a variety of cartridges, diseases such as pneumonia or implant and tissue infections can also be diagnosed within 4–5 hours.
- Sep 2020Grant (prize money)$409.7K
- Jul 2020Conventional Debt$5.7M
- May 2019Series C$1.7M
- May 2019Conventional Debt$5.6M
#7
Series B · Hagen, North Rhine Westphalia · founded 2018$84.5Mraised▾
Developer of single-cell multi-omics platform for clinical research and molecular diagnosis. It offers a product portfolio that includes instruments, microfluidic devices, reagents, software analysis, and database solutions that facilitate high-throughput single-cell analysis. It also, offers single cell sequencing services.
- Nov 2021Series B—
- Dec 2020Series A$30M
- Nov 2020Series A$10M
- Sep 2020Series A$30M
#8
Acquired · Mainz, Rhineland-Palatinate · founded 2001 · 4 employees$212.1Mraised▾
Developer of antibody-based drugs for the treatment of solid cancers. The company focuses on the development of a new class of cancer drugs including IMAB362, an antibody-drug candidate for the treatment of gastroesophageal cancer, and IMAB027, a monoclonal antibody to treat ovarian cancer. Its discovery programs are for breast cancer and solid tumors. It also develops Claudetect18.2, a CE marked in vitro diagnostic test to assess the expression levels of claudin-18.2 in the gastroesophageal, pancreatic, lung, and other solid tumors.
- Nov 2013Series E$57.3M
- Nov 2008Series D$82.8M
- Apr 2007Series C$45.5M
- Jul 2005Grant (prize money)$2M
#9
Seed · Berlin, Berlin · founded 2024$1.4Mraised▾
Developer of AI-based platform to analyse genomic mutation detection and prioritization. It allow healthcare professionals in the detection, interpretation, and prioritisation of structural variations throughout the genome that causes specific genetic diseases.
- Sep 2024Seed$1.4M
#10
Series F · Munich, Bavaria · founded 1998 · 3 employees$158.1Mraised▾
Isarna Therapeutics develops TGF-B inhibitors that stimulate the human immune system to effectively treat ophthalmic, fibrotic diseases cancer. Its lead product ISTH0036 for ophthalmology is undergoing Phase 1 trials. Other candidates include ISTH1106 for fibrosis, ISTH0047, and ISTH1047 for oncology which are in pre-clinical stage. Its leading candidate ISTH0036 is a locked nucleic acid-modified antisense oligonucleotide selectively targeting the messenger ribonucleic acid (mRNA) of TGF-β2. The company received FDA orphan drug designation for ISTH0036, for the prevention of scarring post glaucoma filtration surgery.
- Apr 2014Series F$7.6M
- Jan 2014Series F$17.8M
- Jan 2012Series F$11M
- Jul 2011Series E$11.6M
#11
Series B · Freiburg im Breisgau, Baden Wurttemberg · founded 2016 · 74 employees$27.7Mraised▾
SpinDiag, a spin-off of Hahn-Schickard, develops a point-of-care system. The automated system helps in the screening drug-resistant pathogens. The system, LabDisk, is based on a patented centrifugal-microfluidic technology which provides PCR results directly from patient swab samples.
- Oct 2022Conventional Debt$14.6M
- May 2020Series B$17.8M
- Apr 2020Series B$6.5M
- Nov 2018Series A$3.4M
#12
Public · Berlin, Berlin · founded 1998 · 32 employees$53.3Mraised▾
Epigenomics is a molecular diagnostics company developing and commercializing a pipeline of proprietary products for the screening and diagnosis of cancer. Their product portfolio includes Epi proColon®, a blood-based test for the early detection of colorectal cancer and Epi proLung®, a confirmatory test that aids in the diagnosis of lung cancer.Their development pipeline also contains tests for screening, monitoring, diagnosis and prognosis assessment in colorectal and lung cancer.
- Jan 2021Post IPO$6.8M
- Mar 2020Post IPO—
- Nov 2019Post IPO$5.3M
- Jan 2018Grant (prize money)$276.9K
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Genomics coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Bioinformatics is moving in Germany
A read on the academic research around Bioinformatics — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 2,605 Germany-affiliated papers.
- Heidelberg University245
- German Cancer Research Center123
- Charité - Universitätsmedizin Berlin95
- Goethe University Frankfurt94
- Ludwig-Maximilians-Universität München91
- Genome13→106
- Gene16→108
- Transcriptome6→61
- Epigenetics2→40
- Context (archaeology)1→33
- Disease1→62
- Gene3→49
- Immune system1→41
- Transcriptome4→37
- Biomarker1→29
- Disease2→41
- Immune system1→29
- Gene4→24
- Genome2→20
- Cancer1→14
Where bioinformatics is researched across Germany
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.